Omega Therapeutics Inc. (Nasdaq: OMGA)

https://www.omegatherapeutics.com

LinkedIn: https://www.linkedin.com/company/omega-therapeutics

Omega Therapeutics™ is a preclinical stage genomic medicine enterprise transforming medicine and patient care through precision genomic control. The company’s platform is focused on selectively directing the human genome to treat and cure disease by precisely controlling genomic expression without changing nucleic acid sequences. We are developing precision therapeutics for a range of disease indications including rare genetic diseases, immunology, inflammation, metabolic diseases and oncology. Founded by Flagship Pioneering, Omega has created a platform and knowledge base that identifies Insulated Genomic Domains (IGDs) and their biological functions in both healthy and diseased states across cell types. IGDs function as the fundamental regulators, or GenomStats™, of the human genome. This scientific insight drives our discovery and development of genomic modulators called Omega Controllers™, which we engineer to precisely tune genomic activity to desired therapeutic levels without altering the human genetic code. *

	Start	2017-01-01 established
	Industry	Omega Controllers™
	Industry 2	drug development
	Person	Karande, Mahesh (Omega Therapeutics 201909– CEO before Macrolide + Intarcia Therapeutics + Novartis + Ikaria + Pfizer)
	Person 2	Sawhney, Roger (Omega Therapeutics 202009 CFO)

	Region	Cambridge, MA
	Country	United States (USA)
	Street	20 Acorn Park Drive
	City	02140 Cambridge, MA
	Tel	+1-617-949-4360
		Address record changed: 2024-01-05

Basic data	Employees	n. a.

		* Document for »About Section«: Flagship Pioneering. (9/23/19). "Press Release: Flagship Pioneering Unveils Omega Therapeutics and Appoints Seasoned BioPharma Executive Mahesh Karande as President and Chief Executive Officer". Cambridge, MA.

		Record changed: 2024-01-07